CD47 expression regulated by the miR-133a tumor suppressor is a novel prognostic marker in esophageal squamous cell carcinoma

Oncology Reports

Volumn 28, Issue 2, 2012, Pages 465-472

  Suzuki, Shigemasa ^a   Yokobori, Takehiko ^a   Tanaka, Naritaka ^a   Sakai, Makoto ^a   Sano, Akihiko ^a   Inose, Takanori ^a   Sohda, Makoto ^a   Nakajima, Masanobu ^b   Miyazaki, Tatsuya ^a   Kato, Hiroyuki ^b   Kuwano, Hiroyuki ^a  

^a GUNMA UNIVERSITY   (Japan)

^b DOKKYO MEDICAL UNIVERSITY   (Japan)

Author keywords

CD47; Esophageal cancer; MiR 133a

Indexed keywords

CD47 ANTIGEN; MICRORNA; MICRORNA 133A; UNCLASSIFIED DRUG;

ADULT; AGED; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CARCINOGENESIS; CD47 GENE; CONTROLLED STUDY; DOWN REGULATION; ESOPHAGEAL SQUAMOUS CELL CARCINOMA; FEMALE; GENE CONTROL; GENE EXPRESSION REGULATION; GENE FUNCTION; GENETIC ASSOCIATION; GENETIC TRANSFECTION; GROWTH INHIBITION; HUMAN; HUMAN CELL; IN VITRO STUDY; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; MOLECULAR PATHOLOGY; MOUSE; NONHUMAN; ONCOGENE; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; SEQUENCE ANALYSIS; TUMOR XENOGRAFT; WESTERN BLOTTING;

AGED; ANIMALS; ANTIGENS, CD47; CARCINOMA, SQUAMOUS CELL; CELL GROWTH PROCESSES; CELL LINE, TUMOR; ESOPHAGEAL NEOPLASMS; FEMALE; GENE EXPRESSION PROFILING; GENES, TUMOR SUPPRESSOR; HUMANS; MALE; MICE; MICE, INBRED BALB C; MICE, NUDE; MICRORNAS; MIDDLE AGED; PROGNOSIS; TRANSFECTION; TRANSPLANTATION, HETEROLOGOUS; TUMOR MARKERS, BIOLOGICAL; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84863432560     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or.2012.1831     Document Type: Article

References (42)

1. Enzinger PC and Mayer RJ: Esophageal cancer. N Engl J Med 349: 2241-2252, 2003. (Pubitemid 37485141)
2. Parkin DM, Bray F, Ferlay J and Pisani P: Global cancer statistics, 2002. CA Cancer J Clin 55: 74-108, 2005. (Pubitemid 40372904)
3. Malthaner RA, Wong RK, Rumble RB and Zuraw L: Neoadjuvant or adjuvant therapy for resectable esophageal cancer: a systematic review and meta-analysis. BMC Med 2: 35, 2004.
4. Gebski V, Burmeister B, Smithers BM, Foo K, Zalcberg J and Simes J: Survival benefits from neoadjuvant chemoradiotherapy or chemotherapy in oesophageal carcinoma: a meta-analysis. Lancet Oncol 8: 226-234, 2007. (Pubitemid 46291702)
5. Tepper J, Krasna MJ, Niedzwiecki D, et al: Phase III trial of trimodality therapy with cisplatin, fluorouracil, radiotherapy, and surgery compared with surgery alone for esophageal cancer: CALGB 9781. J Clin Oncol 26: 1086-1092, 2008.
6. Shinohara M, Ohyama N, Murata Y, et al: CD47 regulation of epithelial cell spreading and migration, and its signal transduction. Cancer Sci 97: 889-895, 2006. (Pubitemid 44151270)
7. Oldenborg PA, Zheleznyak A, Fang YF, Lagenaur CF, Gresham HD and Lindberg FP: Role of CD47 as a marker of self on red blood cells. Science 288: 2051-2054, 2000. (Pubitemid 30397687)
8. Okazawa H, Motegi S, Ohyama N, et al: Negative regulation of phagocytosis in macrophages by the CD47-SHPS-1 system. J Immunol 174: 2004-2011, 2005. (Pubitemid 40223942)
9. van den Berg TK and van der Schoot CE: Innate immune 'self' recognition: a role for CD47-SIRPalpha interactions in hematopoietic stem cell transplantation. Trends Immunol 29: 203-206, 2008.
10. Oldenborg PA, Gresham HD, Chen Y, Izui S and Lindberg FP: Lethal autoimmune hemolytic anemia in CD47-deficient nonobese diabetic (NOD) mice. Blood 99: 3500-3504, 2002. (Pubitemid 34534515)
11. Jaiswal S, Chao MP, Majeti R and Weissman IL: Macrophages as mediators of tumor immunosurveillance. Trends Immunol 31: 212-219, 2010.
12. Majeti R, Chao MP, Alizadeh AA, et al: CD47 is an adverse prognostic factor and therapeutic antibody target on human acute myeloid leukemia stem cells. Cell 138: 286-299, 2009.
13. Chao MP, Alizadeh AA, Tang C, et al: Therapeutic antibody targeting of CD47 eliminates human acute lymphoblastic leukemia. Cancer Res 71: 1374-1384, 2011.
14. Nagahara M, Mimori K, Kataoka A, et al: Correlated expression of CD47 and SIRPA in bone marrow and in peripheral blood predicts recurrence in breast cancer patients. Clin Cancer Res 16: 4625-4635, 2010.
15. Junker A, Krumbholz M, Eisele S, et al: MicroRNA profiling of multiple sclerosis lesions identifies modulators of the regulatory protein CD47. Brain 132: 3342-3352, 2009.
16. Valencia-Sanchez MA, Liu J, Hannon GJ and Parker R: Control of translation and mRNA degradation by miRNAs and siRNAs. Genes Dev 20: 515-524, 2006. (Pubitemid 43345317)
17. Bartel DP: MicroRNAs: genomics, biogenesis, mechanism, and function. Cell 116: 281-297, 2004.
18. Bartel DP: MicroRNAs: target recognition and regulatory functions. Cell 136: 215-233, 2009.
19. Lu J, Getz G, Miska EA, et al: MicroRNA expression profiles classify human cancers. Nature 435: 834-838, 2005. (Pubitemid 40839735)
20. Volinia S, Calin GA, Liu CG, et al: A microRNA expression signature of human solid tumors defines cancer gene targets. Proc Natl Acad Sci USA 103: 2257-2261, 2006. (Pubitemid 43271657)
21. Guo Y, Chen Z, Zhang L, et al: Distinctive microRNA profiles relating to patient survival in esophageal squamous cell carcinoma. Cancer Res 68: 26-33, 2008. (Pubitemid 351380102)
22. Childs G, Fazzari M, Kung G, et al: Low-level expression of microRNAs let-7d and miR-205 are prognostic markers of head and neck squamous cell carcinoma. Am J Pathol 174: 736-745, 2009.
23. Wong TS, Liu XB, Wong BY, Ng RW, Yuen AP and Wei WI: Mature miR-184 as potential oncogenic microRNA of squamous cell carcinoma of tongue. Clin Cancer Res 14: 2588-2592, 2008.
24. Nohata N, Hanazawa T, Kikkawa N, et al: Caveolin-1 mediates tumor cell migration and invasion and its regulation by miR-133a in head and neck squamous cell carcinoma. Int J Oncol 38: 209-217, 2011.
25. Chiyomaru T, Enokida H, Tatarano S, et al: miR-145 and miR-133a function as tumour suppressors and directly regulate FSCN1 expression in bladder cancer. Br J Cancer 102: 883-891, 2010.
26. Song T, Xia W, Shao N, et al: Differential miRNA expression profiles in bladder urothelial carcinomas. Asian Pac J Cancer Prev 11: 905-911, 2010.
27. Bandres E, Cubedo E, Agirre X, et al: Identification by real-time PCR of 13 mature microRNAs differentially expressed in colorectal cancer and non-tumoral tissues. Mol Cancer 5: 29, 2006.
28. Missiaglia E, Shepherd CJ, Patel S, et al: MicroRNA-206 expression levels correlate with clinical behaviour of rhabdomyosarcomas. Br J Cancer 102: 1769-1777, 2010.
29. Rao PK, Missiaglia E, Shields L, et al: Distinct roles for miR-1 and miR-133a in the proliferation and differentiation of rhabdomyosarcoma cells. FASEB J 24: 3427-3437, 2010.
30. Lewis BP, Burge CB and Bartel DP: Conserved seed pairing, often flanked by adenosines, indicates that thousands of human genes are microRNA targets. Cell 120: 15-20, 2005. (Pubitemid 40094598)
31. Kano M, Seki N, Kikkawa N, et al: miR-145, miR-133a and miR-133b: Tumor suppressive miRNAs target FSCN1 in esophageal squamous cell carcinoma. Int J Cancer 127: 2804-2814, 2010.
32. Hashimoto Y, Ito T, Inoue H, et al: Prognostic significance of fascin overexpression in human esophageal squamous cell carcinoma. Clin Cancer Res 11: 2597-2605, 2005. (Pubitemid 40569459)
33. Wang H, Madariaga ML, Wang S, Van Rooijen N, Oldenborg PA and Yang YG: Lack of CD47 on non-hematopoietic cells induces split macrophage tolerance to CD47null cells. Proc Natl Acad Sci USA 104: 13744-13749, 2007. (Pubitemid 350003391)
34. Kuwano H, Nakajima M, Miyazaki T and Kato H: Distinctive clinicopathological characteristics in esophageal squamous cell carcinoma. Ann Thorac Cardiovasc Surg 9: 6-13, 2003.
35. Nagata H, Arai T, Soejima Y, Suzuki H, Ishii H and Hibi T: Limited capability of regional lymph nodes to eradicate metastatic cancer cells. Cancer Res 64: 8239-8248, 2004. (Pubitemid 39491761)
36. Asano K, Nabeyama A, Miyake Y, et al: CD169-positive macrophages dominate antitumor immunity by crosspresenting dead cell-associated antigens. Immunity 34: 85-95, 2011.
37. Soifer HS, Rossi JJ and Saetrom P: MicroRNAs in disease and potential therapeutic applications. Mol Ther 15: 2070-2079, 2007. (Pubitemid 350148921)
38. Elmen J, Lindow M, Schutz S, Lawrence M, et al: LNA-mediated microRNA silencing in non-human primates. Nature 452: 896-899, 2008. (Pubitemid 351550859)
39. Silvestri P, Di Russo C, Rigattieri S, et al: MicroRNAs and ischemic heart disease: towards a better comprehension of pathogenesis, new diagnostic tools and new therapeutic targets. Recent Pat Cardiovasc Drug Discov 4: 109-118, 2009.
40. Chan KS, Espinosa I, Chao M, et al: Identification, molecular characterization, clinical prognosis, and therapeutic targeting of human bladder tumor-initiating cells. Proc Natl Acad Sci USA 106: 14016-14021, 2009.
41. Chao MP, Alizadeh AA, Tang C, et al: Anti-CD47 antibody synergizes with rituximab to promote phagocytosis and eradicate non-Hodgkin lymphoma. Cell 142: 699-713, 2010.
42. Chao MP, Alizadeh AA, Tang C, et al: Therapeutic antibody targeting of CD47 eliminates human acute lymphoblastic leukemia. Cancer Res 71: 1374-1384, 2010.